Hevea brasiliensis latex dialysed C-serum precipitate subfraction exerts a negligible level of genotoxicity in the Ames test, mouse lymphoma assay and micronucleus assay

Dialysed C-serum precipitate (DCP), a sub-fraction of latex C-serum originating from Hevea brasiliensis, has shown specific in vitro antiproliferative properties towards cancer-origin cell lines. As a potential agent to be used in cancer treatment, preclinical safety assessment tests are crucial. This study focused on investigating the mutagenicity of DCP via bacterial reverse mutation assay (Ames test), Mouse lymphoma assay (MLA), and micronucleus assay according to OECD guidelines. No mutagenicity was exhibited by DCP at concentrations lower than 1 mg/mL for the five different auxotroph strains of Salmonella typhimurium (TA 98, TA 100, TA 1535, and TA 1537) and Escherichia coli WP2uvrA pKM101 in the absence and presence of metabolic activation system (S9-mix). Nonetheless, it has been found that DCP was able to induce negligible mutation in MLA and micronucleus assay. Overall, DCP does express dose-dependant mutagenicity according to the assays conducted and thus, it is crucial to take this into consideration should DCP be used in the development of therapeutic agent.